Health
TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) versus investigator's choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refract
About this update from Johnson & Johnson
[{"type":"text","content":"First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line","length":160,"tagName":"p","attribs":{}},{"type":"image","alt":"(PRNewsfoto/Johnson & Johnson)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Johnson & Johnson)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":37,"url":"https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YyQxtwHN0OWd0z9HyFy.lg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","width":400,"height":37}},"href":"https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"RARITAN, N.J., Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) versus investigator's choice of DARZALEX FASPRO, pomalidomide, and dexamethasone (DPd) or DARZALEX FASPRO, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) who received one to three prior lines of therapy.1","length":636,"tagName":"p"},{"type":"text","content":"At almost three years follow-up, the combination of TECVAYLI and DARZALEX FASPRO met the primary endpoint of progression-free survival (PFS) (the time a treatment keeps a patient's cancer from progressing or death) and the results were statistically significant and superior to standard of care.2 The secondary endpoint of overall survival (OS) was also statistically significant at this first interim analysis.2","length":416,"tagName":"p"},{"type":"text","content":""TECVAYLI is the most utilized BCMA bispecific in later lines of myeloma treatment, supported by extensive clinical and real-world ...